In a first-in-human trial (NI006-101), the monoclonal antibody cliramitug, targeting misfolded transthyretin, demonstrated a favorable safety profile and time- and dose-dependent reductions in surrogate markers of cardiac amyloid burden over the course of 12 months in patients with amyloid transthyretin cardiomyopathy (ATTR-CM). 

Read full article ( Nat Med 2026 Jun 26) here!

This new definition of MINOCA, replacing the ‘I’ for infarction with the ‘I’ for injury, better reflects the working diagnosis nature of this terminology, whilst also emphasizing the need for further invasive and non-invasive testing to identify the final diagnosis, which can be epicardial, microvascular, myocardial, and non-cardiac.

Read the full article (European Heart Journal (2026) 00, 1–4) here!

Cardiovascular disease remains Europe’s leading cause of death, and addressing this burden requires visibility, credibility and coordinated action. The new ESC website, www.escardio.org, is a strategic tool for the ESC to reinforce its role as a trusted scientific and public health partner at European and global level.

Read full article (ESC Officers Newsletter- Issue 3, Summer 2026) here!

This 2025 report from the ESC Atlas project is the fifth in a biennial series. It presents and compares updated cardiovascular disease (CVD) statistics for more than 50 of the ESC member countries. 

Read full article (European Heart Journal (2026) 00, 1–45) here!

This study aimed to assess whether JCAD serves as a novel marker of or target to address residual risk.

Read full article (European Heart Journal (2025) 00, 1–15) here!

Die kardiovaskuläre Bildgebung entwickelt sich zu einem zentralen Instrument der personalisierten Therapie der koronaren Herzkrankheit.

Lesen sie den vollständigen Artikel (Therapeutische Umschau 2026; 83 (3): 240–244) hier!
 

The article outlines urgent research needs, such as the need for high-resolution exposure data, exploration of gene–environment interactions and molecular pathways, and the development of real-world and mechanistic studies assessing interventions. 

Read full article (European Heart Journal (2026) 00, 1–25) here!

This study aimed to investigate the association of baseline serum levels of CCN1, NT-proBNP, hsTnT, and PCSK9 with CMR-derived infarct characteristics assessed 30 days after acute STEMI in the intermediate post-infarction stage.

Read full article (IJC Heart & Vasculature 64 (2026) 101918) here!
 

High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker...

Read full article (European Heart Journal (2026) 47, 1799–1810) here!

As the European Society of Cardiology (ESC) matured, the leadership looked beyond education, congresses, and scientific journals. Indeed, to serve its members and address its mission of reducing the burden of cardiovascular disease, it seemed necessary to raise its voice at the European level and its institutions in Brussels. 

Read the full article (European Heart Journal (2026) 00, 1–5) here!